Heart failure & cardiomyopathies
A cost-effectiveness analysis of hypertrophic cardiomyopathy sudden cardiac death risk algorithms for implantable cardioverter defibrillator decision-making
Main finding · Cost-effectivenessResult — go to the resultIncremental cost-effectiveness ratio £834 per QALYAuthors' conclusion
While we have shown that a 6% 5-year SCD risk cut-off provides the best cohort stratification to aid ICD decision-making, this will also be influenced by the particular values of costs and HRQL for subgroups or at a local level.
Study context
- Population
- Patients with hypertrophic cardiomyopathy considered for primary-prevention ICD
- Comparison
- ICD decision-making rules vs current real-world practice
- Outcome
- Cost-effectiveness (cost per QALY)
- Follow-up
- 12-year time horizon
Methodological detailsdiscrete-time Markov model, 12-year time horizon, Bayesian analysis of transition probabilities, Reported per CHEERS checklist
- Discrete-time Markov model
- 12-year time horizon
- Bayesian analysis of transition probabilities
- Reported per CHEERS checklist
Main finding
Cost-effectiveness
Incremental cost-effectiveness ratio
£834 per QALY
As reported in the abstract
Further findings
Sensitivity analyses
- Decision largely driven by health-related quality of life (HRQL) attributed to ICD patients and time horizon
Original publication
A cost-effectiveness analysis of hypertrophic cardiomyopathy sudden cardiac death risk algorithms for implantable cardioverter defibrillator decision-making. Eur Heart J Qual Care Clin Outcomes. Published 2 September 2023. doi:10.
Summarised from the published abstract; every number is checked against it